3d agoInvestorsHubBEARISH 32Product/PR
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data
Tyra Biosciences shares fall 30% after the company releases initial Phase 2 SURF302 trial results for dabogratinib in bladder cancer.
Archived explainer. For the current picture see today's TYRA page.
Why Is TYRA BIOSCIENCES INC (TYRA) Stock Down Today?
By the Top Tier Newswire AI Desk · September 9, 2026 at 10:22 AM ET · reviewed against 10 wire stories
TYRA BIOSCIENCES INC (TYRA) is down -21.49% in the latest session. Our newswire has captured 10 stories on TYRA across 8 sources in the last 36 hours, with AI sentiment reading mixed (avg 49/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why TYRA stock is down today
Tyra Biosciences stock fell 21.49% to $20.99 in a volatile session driven by the release of initial Phase 2 SURF302 trial results for its lead candidate, dabogratinib, in the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). The data showed a 79% overall response rate and 64% complete response rate at a 60 mg daily dose, but the market reacted negatively to the results, which may not have met expectations for a breakthrough.
What Happened
Tyra Biosciences announced the initial results of the Phase 2 SURF302 trial, which evaluated dabogratinib as an oral treatment for LG IR NMIBC. The trial reported a 79% overall response rate and 64% best overall complete response rate at the 60 mg dose. While the company highlighted favorable safety and tolerability results that support chronic dosing potential, the stock plummeted in response. The 8-K filing on September 9 confirmed the release of the data and other events. The stock opened with a modest 0.9% gap up at $26.96 but quickly reversed course, hitting a session low of $16.34 before closing at $20.98.
What The Data Shows
The stock’s intraday performance was highly volatile, with a session high of $28.50 and a low of $16.34. The volume of 2.4 million shares was 3.2 times the 3-month average. Over the previous eight sessions, the stock had risen 9.9% from $26.13 to $28.72. Despite the recent rally, the stock closed below its 52-week range of $11.70 to $40.65. Additionally, unusual options activity showed a notable put premium of $332K, indicating bearish sentiment. The stock also printed nine fresh 52-week highs on September 9, highlighting the recent strength and volatility.
What To Watch
Tyra Biosciences is scheduled to discuss the initial results from the SURF302 Phase 2 study in a conference call and webcast. Investors will be monitoring the company’s presentation and the broader market reaction to the data. Coverage breadth and analyst commentary will also be key to watch in the coming days.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TYRA by the numbers
Last: $20.99Session: -21.49%7 sessions: -16.18%Coverage: 10 stories / 8 sourcesAI sentiment: 49/100 (mixed)Mkt cap: $1.7B52w: $11.70 to $40.65
The headlines behind the move
3d agoInvesting.com MarketsBEARISH 32General
Why is Tyra Biosciences stock plunging today?
Why is Tyra Biosciences stock plunging today?
3d agoInvesting.com MarketsBEARISH 28Earnings
Tyra Biosciences stock tumbles 30% on phase 2 trial results
Tyra Biosciences stock tumbles 30% on phase 2 trial results
4d agoSeeking AlphaBEARISH 32Product/PR
Tyra drops after mid-stage trial data for lead asset in bladder cancer
Tyra Biosciences (TYRA) stock slides as the company posts initial results from a Phase 2 trial for its lead candidate dabogratinib in bladder cancer. Read more here.
4d agoTipRanksBULLISH 67Product/PR
Tyra Bioscience Reports Promising Phase 2 Dabogratinib Data
4d agoSEC 8-KNEUTRAL 50General
Tyra Biosciences, Inc. (TYRA) files 8-K
Filed: 2026-09-09 AccNo: 0001193125-26-385886 Size: 168 KB Item 8.01: Other Events
4d agoThe FlyBULLISH 63Product/PR
Tyra Biosciences reports results from Phase 2 study of SURF302
4d agoPR NewswireBULLISH 67Product/PR
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC Favorable safety and tolerability results support chronic dosing potential No clinically significant hyperphosphatemia, nail toxicity or ocular toxicity; low frequency of...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on TYRA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier TYRA move explainers: 2026-09-11 · 2026-09-10 · 2026-09-09 · 2026-09-08 · 2026-09-04